Xencor Reaches Research Milestone (BW Healthwire)–June 17, 2002—Monrovia, CA – Xencor today announced that it has reached a major milestone in its research agreement with Syngenta’s (NYSE: SYT) Torrey Mesa Research Institute (TMRI). In just six months, half the time agreed upon, Xencor has created
Enhancing The Therapeutic Utility of Biopharmaceuticals: The Next Frontier (BW Healthwire)–June 04, 2002—Xencor’s Vice President, Discovery Technologies, Robert Pacifici, Ph.D., Presents at BIO 2002, June 10 at 10:30 a.m.-12:00 p.m. in room 701A. Monrovia, CA – Xencor, a drug discovery company
Xencor Expands Protein Optimization Technology To Develop Next-Generation Biotechnology Products (BW Healthwire)–February 20, 2002—Monrovia, CA – February 20, 2002 – Xencor today announced that it has signed licensing agreements with the California Institute of Technology and Pennsylvania State
Syngenta’s Torrey Mesa Research Institute And Xencor Sign Research And License Agreement (BW Healthwire)–January 03, 2002—La Jolla, CA and Monrovia, CA.- January 3, 2002 -Torrey Mesa Research Institute (TMRI), a wholly owned subsidiary of Syngenta (NYSE: SYT), today announced the signing of a three
Xencor Expands Management Team To Lead Drug Discovery And Protein Optimization Programs (BW Healthwire)–October 09, 2001—Xencor today announced that Stephen K. Doberstein, Ph.D. has joined as Vice President, Chemical Biology and Robert E. Pacifici, Ph.D.
Xencor Receives Two Patents For Ultra-Fast Optimization Technology To Create A New Generation Of Biotechnology Products Xencor Receives Two Patents For Ultra-Fast Optimization Technology To Create A New Generation Of Biotechnology Products (BW Healthwire)–August 06, 2001—Protein Design Automation™
Xencor Receives SBIR Phase II Grant for High Throughput Screening of Novel Computationally Derived Optimized Proteins (BW Healthwire)–June 19, 2001—Paves the Way for Improved Biopharmaceuticals and New Industrial and Agricultural Products Xencor today announced that the company has been awarded a